STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
Source ↗
👁 2
💬 0
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. As an avid Pilates goer, I appreciated this story.
The need-to-know this morning
Roche reported a positive Phase 2 trial of enicepatide (previously known as CT-388) in patients with type 2 diabetes and obesity, with the drug helping patients lose weight and lower blood sugar. The company already has two Phase 3 weight loss studies ongoing a
Good morning. As an avid Pilates goer, I appreciated this story.
The need-to-know this morning
Roche reported a positive Phase 2 trial of enicepatide (previously known as CT-388) in patients with type 2 diabetes and obesity, with the drug helping patients lose weight and lower blood sugar. The company already has two Phase 3 weight loss studies ongoing a
Comments (0)